Duloxetine
Product Images NDC 50436-2892

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50436-2892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

00228289203

Two views of a Duloxetine capsule imprinted with the code '2892' and a partial circular logo on both ends. The capsule is half opaque white and half translucent off-white, showing no additional markings or colors.*

FDA Label Image

1 (Duloxetine 1)

FDA Label Image

6 (Duloxetine 10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine Delayed-Release at doses of 120 mg, 60 mg, and 20 mg once daily compared to placebo. The graph illustrates that higher doses of Duloxetine correspond with greater patient improvement compared to placebo.*

FDA Label Image

7 (Duloxetine 11)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows percentage of patients improved from 0 to 100%. Two lines represent duloxetine and placebo results over the range.*

FDA Label Image

8 (Duloxetine 12)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing data for Duloxetine Delayed-Release 60 mg once daily and placebo. The x-axis represents percent improvement in pain, while the y-axis represents the percentage of patients improved. Two lines depict the effect of duloxetine and placebo over the range of improvement percentages.*

FDA Label Image

1 (Duloxetine 13)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). Two lines compare Placebo and Duloxetine Delayed-Release 60/120 mg Once Daily, depicting patient improvement across pain improvement percentages from greater than 0 to 100.*

FDA Label Image

1 (Duloxetine 2)

The image shows a unit dose blister card labeled Duloxetine. It features a single row of five oval pink tablets individually sealed. The label includes the proprietary name Duloxetine and the labeler Unit Dose Services. No specific strength or dosage form details are visible.*

FDA Label Image

1 (Duloxetine 3)

FDA Label Image

1 (Duloxetine 4)

Chemical structure diagram of duloxetine hydrochloride showing its molecular framework including aromatic rings, oxygen, sulfur, nitrogen, and associated atoms as depicted in the image.*

FDA Label Image

1 (Duloxetine 5)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between placebo and Duloxetine extended-release capsules. The y-axis shows the proportion of patients with relapse, and the x-axis shows days from 0 to 250. The placebo group is represented by a dashed line showing a higher relapse rate, while the Duloxetine group is shown with a solid line indicating a lower relapse rate over the 200-day period.*

FDA Label Image

2 (Duloxetine 6)

A Kaplan-Meier plot showing the proportion of patients with relapse over time in days from randomization, comparing placebo and duloxetine delayed-release treatments. The graph depicts relapse rates with placebo higher than those with duloxetine delayed-release across the observed period up to 250 days.*

FDA Label Image

3 (Duloxetine 7)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares Duloxetine delayed-release at doses of 60 mg twice daily, 60 mg once daily, and 20 mg once daily, alongside a placebo group. Different symbols represent each group, and the overall trend shows varying degrees of patient improvement with the treatments versus placebo.*

FDA Label Image

4 (Duloxetine 8)

A line graph comparing percentage improvement in pain from baseline against the percentage of patients improved, for Duloxetine delayed-release 60 mg administered once daily and twice daily, and placebo groups. The graph illustrates patient response rates over a range of improvement percentages.*

FDA Label Image

1 (Duloxetine 9)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine Delayed-Release 60 mg twice daily, Duloxetine Delayed-Release 60 mg once daily, and placebo, illustrating patient response differences across pain improvement percentages.*

FDA Label Image

Label Image (Lbl504362892)

Duloxetine Hydrochloride delayed-release capsules 60 mg, pack of 30, labeled by Unit Dose Services. The label includes dosage information, storage instructions, manufacturer details (Actavis Elizabeth, LLC, Elizabeth, NJ), and space for lot number and expiration date. The product is marked as prescription only (RX ONLY).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.